scholarly journals Predictive value of serological factors, maximal standardized uptake value and ratio of Ki67 in patients diagnosed with non‑Hodgkin's lymphoma

2020 ◽  
Author(s):  
Jinyuan Lu ◽  
You Wu ◽  
Bing Li ◽  
Xiu Luo ◽  
Wenjun Zhang ◽  
...  
Keyword(s):  
Predictive Value ◽  
Hodgkin’S Lymphoma ◽  
Standardized Uptake Value ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Maximal Standardized Uptake Value

scholarly journals Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma

Leukemia ◽  
2006 ◽  
Vol 21 (1) ◽  
pp. 184-187 ◽  
Author(s):  
J F Modiano ◽  
M Breen ◽  
V E O Valli ◽  
J W Wojcieszyn ◽  
G R Cutter
Keyword(s):  
Predictive Value ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Naturally Occurring ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

AgNORs Predictive Value of Prognosis in Non-Hodgkin's Lymphoma: Comparison with Flow Cytometric Cell Cycle Analysis

1992 ◽  
Vol 7 (1-2) ◽  
pp. 165-170 ◽  
Author(s):  
Jasminka Jakić-Razumović ◽  
Branka Uźarević ◽  
Mladen Petrovčeki ◽  
Matko Marušlć ◽  
Ivo Radman ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Predictive Value ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Cell Cycle Analysis ◽  
Flow Cytometric ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Flow Cytometric Cell

Response Assessment After Induction Therapy in Diffuse Large B Cell Lymphoma (DLBCL): Role of Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) in Comparison with Computed Tomography (CT).

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4995-4995 ◽  
Author(s):  
Benedetta Puccini ◽  
Luigi Rigacci ◽  
Patrizia Pregno ◽  
Annalisa Chiappella ◽  
Renato Alterini ◽  
...  
Keyword(s):  
Predictive Value ◽  
Fdg Pet ◽  
Hodgkin’S Lymphoma ◽  
False Negative ◽  
Response Assessment ◽  
Hodgkin's Lymphoma ◽  
Bulky Disease ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Abstract 4995 Background The response evaluation is performed by computed tomography (CT) as a standard tool in DLBCL. The introduction the FDG-PET performed for post treatment response assessment of aggressive Non Hodgkin's Lymphoma (NHL) is advised by the Revised International Workshop Criteria (IWC). We explored the predictive value by FDG-PET scan performed at the end of therapy in patients (pts) with DLBCL treated with rituximab-containing regimens . Patients From 2003 at 2008 were included 86 pts with DLBCL treated with Rituximab and CHOP or CHOP-like regimens. The FDG-PET and CT was mandatory at baseline and at the end of therapy to include pts in the study. We evaluated the progression free survival (PFS) of pts starting from the time of diagnosis to early relapse or disease progression or last follow-up. Results Median age was 60 years (28-78), 40 pts were female and 46 male, 38 pts presented stage I-II and 48 stage III-IV. The International Prognostic Index (IPI) was low in 20% of pts, low-intermediate in 50%, intermediate-high in 28% and high risk in 2%; bulky was reported in 24 pts. Seventy-seven pts attained complete remission (CR) (89%), 8 pts (9%) partial remission (PR) and 1 pts progression disease (2%). The FDG-PET and CT performed at the end of therapy were both negative in 61 pts (71%); both positive in 9 pts (10%). In the remaining pts the FDG-PET and CT scan performed post therapy were discordant in particular in 13 pts (15%) FDG-PET was negative and CT was positive and in 3 pts (4%) FDG-PET was positive and CT was negative. Thus the positive predictive value of a FDG-PET at the end of therapy was 63% and the negative predictive value was 87%. The sensitivity and specificity of FDG-PET at the end of therapy were 41% and 94% respectively. The positive predictive value and the negative predictive value of a CT at the end of therapy were 43% and 87% respectively. The sensitivity of CT at the end of therapy was 53% and the specificity was 83%. Fifthteen out seventy-four patients (20%) with negative FDG-PET progress or relapse within 6 months (median 4 months). Five out twenty (25%) FDG-PET negative bulky disease pts progress or relapse within 6 months moreover four out seventeen (24%) CT negative bulky disease pts progress or relapse. With a median follow-up of 20 months (range 7-83) the overall survival was 86%, and with a median follow-up of 15 months (range 2-78) the PFS was 76%. Conclusions FDG-PET shows an high specificity but a very low sensibility in DLBCL. An high rate of false negative FDG-PET was observed in bulky disease patients. We have observed that pts with negative FDG-PET presented a rapid relapse or progression therefore we can consider that probably in non-Hodgkin's lymphoma PET should be performed after four months from the end of therapy to reduce false negative. Obviously larger study are needed but at the moment CT remain the most sensible instrument to define CR in non-Hodgkin's lymphoma. Disclosures Vitolo: Roche:.

Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Significance ◽  
Antiphospholipid Antibodies ◽  
Myeloid Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Tnf Alpha ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

Sign in / Sign up

Export Citation Format

Share Document